Evidence map›Paper›PMID 36951273›Full record

ArticleCell cycle (Georgetown, Tex.)2023

Impact of

Baofeng Wang, Xiaobin Ma, Wenjie Zhang, Liang Li, Ying Zan, Jianshui Zhan, Xufeng Guo, Ming Lei, Hongbing Ma

Open access · greenAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Baofeng WangDepartment of Radiation Therapy, Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
Xiaobin MaDepartment of Oncology, Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
Wenjie ZhangProvincial Key Laboratory of Biotechnology of Shaanxi Province, Northwest University, Xi'an, China.
Liang LiDepartment of Radiotherapy, Shaanxi Provincial Cancer Hospital Affiliated to Medical College, Xi'an Jiaotong University, Xi'an, China.
Ying ZanDepartment of Oncology, Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
Jianshui ZhanDepartment of Human Anatomy and Tissue embryology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, China.
Xufeng GuoDepartment of Orthopedic, Xi'an Ninth Hospital, Xi'an, China.
Ming LeiDepartment of Radiology, Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
Hongbing MaDepartment of Radiation Therapy, Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
Second Affiliated Hospital of Xi'an Jiaotong University · CNNorthwest University · CNShaanxi Provincial People's Hospital · CNWuxi Ninth People's Hospital · CNXi'an Jiaotong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

NOTCH1, a member of the Notch family, is up-expression in advanced liver cancer (LC) patients and is associated with tumor sizes, tumor stage, metastasis, and invasion. A few studies have discovered the contribution of NOTCH1 variants to LC risk. Our purpose was to assess the relationship of NOTCH1 rs10521, rs2229971, and rs4489420 to LC risk. We enrolled 709 LC patients and 708 healthy controls. Genotyping was determined through the Agena MassARRAY system. Multiple genetic models by logistic regression were useful for odds ratios (ORs) with 95% confidence intervals (CIs). Rs10521-G (p = 0.009, OR = 0.75, 95% CI: 0.61-0.93), rs2229971-A (p = 0.023, OR = 0.81, 95% CI: 0.67-0.97), and rs4489420-A (p = 0.014, OR = 0.38, 95% CI: 0.16-0.85) might be protective factors for LC occurrence in the Chinese Han population, especially rs10521 and rs2229971 (false-positive report probability (FPRP) <0.2 and statistical power >90%). Interestingly, stratified analysis displayed that the contribution of NOTCH1 polymorphisms to LC risk might be associated with gender, age, smoking, and drinking. Our data first determined that NOTCH1 rs10521-G, rs2229971-A, and rs4489420-A might be protective factors for LC susceptibility.

Indexed as

Genetic Predisposition to DiseaseLiver NeoplasmsReceptor, Notch1Case-Control StudiesEast Asian PeopleGenotypeHumansPolymorphism, Single NucleotideNOTCH1 protein, humanReceptor, Notch1Liver cancermultifactor dimensionality reductionNOTCH1 polymorphismsstratification analysis

Identifiers

PMID36951273
PMCPMC10081089
OpenAlexW4360599745

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.